(Q36764903)

16 August 2017

1 reference

title

Dendritic cell-based active specific immunotherapy for malignant glioma (English)

1 reference

16 August 2017

1 reference

1 reference

Prahlad Parajuli

1

1 reference

16 August 2017

Saroj Mathupala

series ordinal

2

1 reference

16 August 2017

Sandeep Mittal

series ordinal

3

1 reference

16 August 2017

Andrew E Sloan

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

4

1 reference

16 August 2017

439-448

1 reference

Dendritic cell-based immunotherapy of malignant gliomas

16 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Predictive and prognostic markers in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Cytokine immuno-gene therapy for treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Dendritic cells in vaccination therapies of human malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Cellular immunotherapy with dendritic cells in cancer: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Cytokines and immunoregulatory molecules in malignant glial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Malignant glioma modulation of immune function: relative contribution of different soluble factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Lipopolysaccharides-activated human astroglioma cells induce apoptotic death of T-lymphocytes via c-Jun N-terminal kinases-dependent up-regulation of TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

Modulation of the immune response by transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.439

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.439

1 reference

16 August 2017

1 reference